Filament Health Corp - Benjamin Lightburn, CEO and Co Founder
Benjamin Lightburn, CEO and Co Founder
Source: YouTube
  • Filament Health (FH) has signed a licensing agreement with ATMA Journey Centers
  • Filament has licensed PEX010 (25mg), a naturally-extracted botanical drug candidate, to ATMA for use in clinical trials
  • ATMA is striving to bring psychedelic-assisted therapy to the clinic
  • Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company
  • Filament Health Corp. (FH) opened trading at C$0.16 on the NEO Exchange

Filament Health (FH) has signed a licensing agreement with ATMA Journey Centers.

ATMA is Canada’s first private therapy company to conduct legal psilocybin therapy through the Health Canada Section 56 Exemption, assisting Canadians facing end-of-life distress from a terminal illness.

Under the agreement, Filament has licensed PEX010 (25mg), a naturally-extracted botanical drug candidate, to ATMA for use in clinical trials. This includes a phase I psilocybin safety trial in healthy individuals enrolled in a psychedelic-assisted therapy training program, for which ATMA recently received Health Canada approval.

“The selection of our natural psilocybin drug candidate for ATMA’s future clinical trials is a validation of both our product and the ease of working with Filament Health,” said Filament Chief Executive Officer, Benjamin Lightburn.

“ATMA is a leader in psychedelic-assisted psychotherapy and we are thrilled that they will be using our product,” he added.

David Harder, Co-Chief Executive Officer at ATMA remarked on the agreement.

“Filament’s candidate was an attractive option because they are a licensed manufacturer and their drug candidate has received approval from Health Canada to enter into multiple human clinical trials. We are proud to support a thriving domestic psychedelics industry by selecting Filament’s natural, Canadian-made drug candidate for future studies.”

ATMA is striving to bring psychedelic-assisted therapy to the clinic. ATMA and Filament Health believe the best way this is achieved is through clinical trials, demonstrating both safety and efficacy, for a variety of mental health indications.

Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company.

Filament Health Corp. (FH) opened trading at C$0.16 on the NEO Exchange.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.